Meeting
2023 ASCO Annual Meeting
Long-term safety of avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC) in the JAVELIN Bladder 100 trial.
Presenter
Joaquim Bellmunt, MD, PhD
Dana-Farber Cancer Institute, Harvard Medical School
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Poster Discussion Session
Session Title
Genitourinary Cancer—Kidney and Bladder
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Urothelial Cancer - Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT02603432
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 4516)
DOI
10.1200/JCO.2023.41.16_suppl.4516
Abstract #
4516
Poster Bd #
8
Abstract Disclosures
Similar Videos & Slides
Speaker: Magdalena Thurin, PhD
Videos & Slides
2024 ASCO Annual Meeting
Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC): Long-term outcomes from the JAVELIN Bladder 100 trial in patients (pts) with histological subtypes.
Speaker: Yohann Loriot, MD, PhD
Videos & Slides
2024 ASCO Genitourinary Cancers Symposium
Avelumab first-line maintenance (1LM) for advanced urothelial carcinoma (aUC): Long-term patient-reported outcomes (PROs) in the phase 3 JAVELIN Bladder 100 trial.
Speaker: Petros Grivas, MD, PhD
Videos & Slides
2024 ASCO Genitourinary Cancers Symposium
Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC): Long-term outcomes from the JAVELIN Bladder 100 trial in patients (pts) with high body mass index (BMI).
Speaker: Jeanny B. Aragon-Ching, MD, FACP